Robeco Institutional Asset Management B.V. Has $56.51 Million Stock Holdings in Exelixis, Inc. $EXEL

Robeco Institutional Asset Management B.V. grew its position in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 31.5% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,289,291 shares of the biotechnology company’s stock after purchasing an additional 309,046 shares during the period. Robeco Institutional Asset Management B.V.’s holdings in Exelixis were worth $56,510,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Richardson Financial Services Inc. boosted its stake in shares of Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 292 shares in the last quarter. Anchor Investment Management LLC boosted its stake in shares of Exelixis by 500.0% during the third quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Root Financial Partners LLC acquired a new stake in shares of Exelixis during the third quarter valued at about $28,000. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Exelixis by 1,380.4% during the third quarter. Northwestern Mutual Wealth Management Co. now owns 829 shares of the biotechnology company’s stock valued at $34,000 after purchasing an additional 773 shares in the last quarter. Finally, V Square Quantitative Management LLC acquired a new stake in shares of Exelixis during the fourth quarter valued at about $44,000. 85.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on EXEL. Weiss Ratings restated a “buy (b)” rating on shares of Exelixis in a research report on Thursday, January 22nd. Stifel Nicolaus raised their price objective on Exelixis from $43.00 to $44.00 and gave the stock a “hold” rating in a research report on Wednesday, February 11th. Bank of America downgraded Exelixis from a “neutral” rating to an “underperform” rating and set a $41.00 price objective for the company. in a research report on Monday, January 5th. Zacks Research downgraded Exelixis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, March 5th. Finally, Wall Street Zen upgraded Exelixis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 14th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat, Exelixis currently has an average rating of “Hold” and an average price target of $46.94.

Check Out Our Latest Stock Analysis on EXEL

Insider Activity at Exelixis

In other news, EVP Dana Aftab sold 47,918 shares of the firm’s stock in a transaction that occurred on Tuesday, February 24th. The shares were sold at an average price of $44.50, for a total transaction of $2,132,351.00. Following the completion of the sale, the executive vice president owned 616,106 shares of the company’s stock, valued at $27,416,717. This trade represents a 7.22% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Patrick J. Haley sold 67,814 shares of the firm’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $43.52, for a total transaction of $2,951,265.28. Following the sale, the executive vice president directly owned 381,908 shares of the company’s stock, valued at approximately $16,620,636.16. This trade represents a 15.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 362,849 shares of company stock worth $15,917,463. Corporate insiders own 2.85% of the company’s stock.

Exelixis Price Performance

Shares of EXEL opened at $44.96 on Tuesday. Exelixis, Inc. has a 1 year low of $33.76 and a 1 year high of $49.62. The company has a market capitalization of $11.68 billion, a price-to-earnings ratio of 16.23, a price-to-earnings-growth ratio of 0.99 and a beta of 0.42. The business has a 50-day moving average of $42.89 and a 200-day moving average of $42.34.

Exelixis (NASDAQ:EXEL – Get Free Report) last issued its earnings results on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.20. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business had revenue of $598.66 million during the quarter, compared to the consensus estimate of $609.17 million. During the same period in the previous year, the company posted $0.55 earnings per share. The firm’s revenue for the quarter was up 5.6% on a year-over-year basis. As a group, sell-side analysts anticipate that Exelixis, Inc. will post 2.04 EPS for the current year.

Exelixis Company Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.

Featured Articles

• Five stocks we like better than Exelixis

Want to see what other hedge funds are holding EXEL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exelixis, Inc. (NASDAQ:EXEL – Free Report).